Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.5898
-$0.0102-1.70%
| Weiss Ratings | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.92 | |||
| Price History | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -41.95% | |||
| 30-Day Total Return | -58.42% | |||
| 60-Day Total Return | -68.81% | |||
| 90-Day Total Return | -49.02% | |||
| Year to Date Total Return | -70.83% | |||
| 1-Year Total Return | -83.85% | |||
| 2-Year Total Return | -87.36% | |||
| 3-Year Total Return | -74.73% | |||
| 5-Year Total Return | -94.44% | |||
| 52-Week High % Change | -85.98% | |||
| 52-Week Low % Change | 23.71% | |||
| Price | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.28 | |||
| 52-Week Low Price | $0.49 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Dec 09, 2024 | |||
| Valuation | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 27.95M | |||
| Enterprise Value | 14.93M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.12 | |||
| Earnings Per Share Growth | -40.25% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -2.01 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.59 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -0.43 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 33.80M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 408 501 8881 | |||
| Address | 10080 N. Wolfe Road Cupertino, CA 95014 | |||
| Website | www.revivapharma.com | |||
| Country | United States | |||
| Year Founded | 2018 | |||
| Profitability | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -331.33% | |||
| Return on Equity | -- | |||
| Income Statement | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -34.50M | |||
| Net Income (TTM) | -33.38M | |||
| Net Income Avl. to Common (TTM) | -33.38M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 26.27% | |||
| EPS Diluted (TTM) | -1.12 | |||
| EPS Diluted Growth (Q YOY) | 47.92% | |||
| Balance Sheet | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.56M | |||
| Cash Per Share (Q) | $0.16 | |||
| Total Current Assets (Q) | 6.81M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -9.98M | |||
| Current Ratio (Q) | 0.388 | |||
| Book Value Per Share (Q) | -$0.30 | |||
| Total Assets (Q) | 7.63M | |||
| Total Current Liabilities (Q) | 17.53M | |||
| Total Debt (Q) | 83.00K | |||
| Total Liabilities (Q) | 17.61M | |||
| Total Common Equity (Q) | -9.98M | |||
| Cash Flow | RVPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 33.91M | |||
| Net Change in Cash (TTM) | 586.50K | |||
| Levered Free Cash Flow (TTM) | -16.30M | |||
| Cash from Operations (TTM) | -33.32M | |||
